You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 13, 2025

Drugs in ATC Class A07AC


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: A07AC - Imidazole derivatives

A07AC Market Analysis and Financial Projection

The ATC class A07AC (Imidazole derivatives) encompasses a range of therapeutics primarily used as intestinal anti-infectives, with broader applications in antifungal, antiviral, anticancer, and antihypertensive treatments. Below is an analysis of the market dynamics and patent landscape for this class:


Market Dynamics

Growth Drivers

  1. Antifungal Demand: Imidazole derivatives like miconazole dominate antifungal drug markets, driven by rising global fungal infections (e.g., candidiasis, dermatophytosis) and over-the-counter availability[3][10].
  2. Cancer Therapeutics: Derivatives such as Vedotin (used in ADCs like Adcetris® and Polivy®) are pivotal in oncology, with the ADC market expanding due to targeted therapy innovations[2][16].
  3. Mental Health Applications: Rising depression rates fuel demand for imidazole-based antidepressants, with the global antidepressant market projected to grow alongside imidazole derivatives[10][16].
  4. Antiviral Research: Imidazole compounds like 6a, 6b, and 7a–d show high binding affinity to SARS-CoV-2 protease, positioning them as COVID-19 therapeutic candidates[1][9].

Market Size and Projections

  • The imidazole market was valued at $1.5 billion in 2022, expected to reach $2.4 billion by 2030 (CAGR: 6.5%)[13][16].
  • Key regions:
    • North America: Leading due to high cancer/depression prevalence and R&D investments.
    • Asia-Pacific: Fastest growth, driven by healthcare spending and aging populations[10][13].

Challenges

  • Regulatory Hurdles: Strict approval processes for novel derivatives[10].
  • Raw Material Costs: Price volatility impacts production[16].

Patent Landscape

Key Innovations and Players

  1. Antiviral Compounds:

    • Imidazole derivatives 6a, 6b, and 7a–d exhibit strong binding to SARS-CoV-2 protease[1].
    • Docking studies highlight halogen interactions and π-bonding as critical for efficacy[1][9].
  2. ADC Technology:

    • Vedotin (US Patent 7,659,241) combines MMAE cytotoxin with antibodies, protected by secondary patents for formulations and dosing[2].
    • Licensing agreements (e.g., Immunogen’s emtansine patent US5,208,020 licensed to Genentech for Kadcyla®) showcase strategic IP strategies[2].
  3. Synthesis Methods:

    • US3197476A covers 1-acyl imidazole synthesis using ketenes[17].
    • EP0310745B1 details substituted imidazole derivatives for therapeutic applications[12].
  4. Therapeutic Expansions:

    • Hypotensive agents: US4340598A claims imidazole derivatives targeting angiotensin II receptors[8].
    • Anticancer agents: Derivatives like ethyl 2-9-2-methyl-1-H-imidazole-4-yl) acetate show sirtuin inhibition, reducing NSCLC cell viability[9].

Litigation and Licensing

  • Seagen vs. Daiichi Sankyo: Dispute over US Patent 10,808,039 (peptide conjugates) led to invalidation, underscoring IP risks in ADC development[2].
  • Strategic licensing (e.g., Immunogen-Genentech) mitigates infringement risks while accelerating commercialization[2].

Competitive Outlook

  • Major Players: Merck, BASF, and Genentech lead in sustainable production and R&D[13][16].
  • Emerging Trends:
    • Green Chemistry: Focus on eco-friendly synthesis[16].
    • Combination Therapies: Patents covering ADC-antibody combinations (e.g., Vedotin with Polivy®)[2].

Key Takeaways

  1. Market Growth: Driven by antifungal, anticancer, and mental health applications.
  2. IP Strategy: Secondary patents for formulations/dosing and strategic licensing are critical.
  3. Innovation Hotspots: Antiviral/anticancer derivatives and ADC technology dominate patent filings.
  4. Regional Shifts: Asia-Pacific’s growth contrasts with North America’s established dominance.

FAQs
Q: Which imidazole derivative is FDA-approved for COVID-19?
A: None yet, but compounds like 6a and 7c show promising in silico activity against SARS-CoV-2[1].

Q: What is Vedotin’s role in ADCs?
A: A linker-cytotoxin combo (MMAE) used in Adcetris® and Polivy®, protected by formulation/dosing patents[2].

Q: How do imidazole derivatives exert anticancer effects?
A: Via sirtuin inhibition, angiogenesis suppression, and chemosensitization[5][9].

Q: Which regions lead imidazole production?
A: North America (R&D) and Asia-Pacific (manufacturing growth)[10][13].

Q: Are imidazole derivatives patent-expired?
A: Core patents (e.g., Vedotin) remain active, while older synthesis methods (e.g., US3197476A) have expired[2][17].


"Imidazole derivatives' structural versatility enables targeted modifications, driving their dominance in antiviral and oncology pipelines." – PMC Analysis[1][9]

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9337989/
  2. https://www.fbrice.com.au/ip-news-insights/traversing-a-dynamic-adc-patent-landscape-2/
  3. https://go.drugbank.com/drugs/DB01110
  4. https://www.drugpatentwatch.com/p/patent/5298520
  5. https://www.ijrar.org/papers/IJRAR22D1010.pdf
  6. https://patents.google.com/patent/US4154738A/en
  7. https://catalogues.ema.europa.eu/sites/default/files/document_files/Aritmo_Deliverable5.2_amended.pdf
  8. https://patents.google.com/patent/US4340598A/en
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC10662127/
  10. https://www.factmr.com/report/3366/imidazole-market
  11. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1622556
  12. https://patents.google.com/patent/EP0310745B1/en
  13. https://www.verifiedmarketreports.com/product/imidazole-products-market/
  14. https://ipwatchdog.com/2017/08/10/immunotherapy-patent-landscape-patent-claims-immunotherapeutic-inventions/id=86634/
  15. https://www.ipstudies.ch/2017/06/june-2017-acceleration-of-the-crispr-patent-landscape-growth/
  16. https://github.com/verifiedmarketreports-sys/Market/blob/main/2/Imidazole-Market-Key-Trends.md
  17. https://patents.google.com/patent/US3197476A/en
Last updated: 2025-03-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.